quinazolines has been researched along with Laryngeal Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birkeland, AC; Bradford, CR; Brenner, JC; Carey, TE; Foltin, SK; Komarck, CM; Ludwig, ML; Mann, JE; McHugh, JB; Michmerhuizen, NL; Prince, ME; Sandelski, MM; Scott, MV; Spector, ME; Tillman, BN; Yanik, M | 1 |
| Batra, RK; Dubinett, SM; Limsukon, A; Soo Hoo, GW; Susanto, I | 1 |
| Ikejima, T; Kang, N; Onodera, S; Qiu, F; Tashiro, S; Zhang, JH | 1 |
| Domínguez-Fernández, I; Eguren, C; García-Díez, A; Santiago-Sánchez-Mateos, DI | 1 |
| Araújo, CM; Bezerra, M; Dias, FL; Federico, MH; Ferreira, CG; Fontão, K; Herchenhorn, D; Knust, RE; Martins, RG; Small, I; Viegas, CM | 1 |
| Andry, G; Awada, A; Bogaerts, J; El-Hariry, I; Fortpied, C; Lacombe, D; Lalami, Y; Langendijk, JA; Liberatoscioli, C; Specenier, PM; Vermorken, JB | 1 |
| Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X | 1 |
| Bostrom, B; Drehner, D; Lander, T; Marker, S; Sidman, J | 1 |
2 trial(s) available for quinazolines and Laryngeal Neoplasms
| Article | Year |
|---|---|
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Drug Administration Schedule; Drug Eruptions; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Quinazolines; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 2010 |
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Induction Chemotherapy; Lapatinib; Laryngeal Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2012 |
6 other study(ies) available for quinazolines and Laryngeal Neoplasms
| Article | Year |
|---|---|
Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.
Topics: Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carbamates; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; ErbB Receptors; Gene Expression Profiling; Humans; Hydroxybutyrates; Immunohistochemistry; Laryngeal Neoplasms; Mouth Neoplasms; Mutation; Purines; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Triazines | 2016 |
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
Topics: Biopsy; Bronchoscopy; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Papilloma; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides | 2009 |
Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Diterpenes, Kaurane; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Fas-Associated Death Domain Protein; Humans; Laryngeal Neoplasms; Membrane Potential, Mitochondrial; Oxidative Stress; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Reactive Oxygen Species; Signal Transduction; Sirtuin 1; Tyrphostins | 2010 |
[Erlotinib-induced acneiform rash not affecting previously irradiated skin].
Topics: Acneiform Eruptions; Antineoplastic Agents; Arm; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Humans; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Neck Dissection; Neoplasm Proteins; Organ Specificity; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Skin; Thorax | 2010 |
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins | 2004 |
Gefitinib therapy for life-threatening laryngeal papillomatosis.
Topics: Adolescent; Antiviral Agents; Bronchoscopy; ErbB Receptors; Gefitinib; Humans; Laryngeal Neoplasms; Male; Papilloma; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Recurrence; Treatment Outcome | 2005 |